Patents by Inventor Paul William Smith
Paul William Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11963703Abstract: A bone cutting guide may include a support that contains a shaft movable relative to the support. The shaft may carry a guide member having one or more cut guides through which a clinician inserts a cutting member to cut bone positioned under the guide cut guides. In operation, a clinician may fixate the support of the bone cutting guide to a bone and translate the guide member until the one or more cut guides are positioned at a desired cut location. The clinician may then perform a cut through the cut guide.Type: GrantFiled: November 30, 2020Date of Patent: April 23, 2024Assignee: Treace Medical Concepts, Inc.Inventors: Paul Dayton, Joe William Ferguson, F. Barry Bays, John T. Treace, W. Bret Smith
-
Patent number: 11951035Abstract: Devices, systems and methods for controlling a patient's body temperature by endovascular heat exchange.Type: GrantFiled: August 11, 2021Date of Patent: April 9, 2024Assignee: ZOLL Circulation, Inc.Inventors: Jeremy Thomas Dabrowiak, Jessica Megan Clayton, John Thomas Buckley, Christo P. Pamichev, Craig Wendell Pendry, Paul Eric Peterson, Richard Allen Smith, Sean W. Yip, John William Jacobsen
-
Publication number: 20210032202Abstract: A compound of Formula (1) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R1, R2, R3, R4, R5 and R6 are as defined herein.Type: ApplicationFiled: June 12, 2020Publication date: February 4, 2021Inventors: Jan JIRICEK, Ravinder Reddy KONDREDDI, Paul William SMITH
-
Publication number: 20160355477Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R1, R2, R3, R4, R5 and R6 are as defined herein.Type: ApplicationFiled: August 19, 2016Publication date: December 8, 2016Applicant: NOVARTIS AGInventors: Jan Jiricek, Ravinder Reddy Kondreddi, Paul William Smith
-
Patent number: 9447039Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R1, R2, R3, R4, R5 and R6 are as defined herein.Type: GrantFiled: September 5, 2013Date of Patent: September 20, 2016Assignee: Novartis AGInventors: Jan Jiricek, Ravinder Reddy Kondreddi, Paul William Smith
-
Publication number: 20150175539Abstract: A compound of Formula (I) is provided that has been shown to be useful for treating a disease, disorder or syndrome that is mediated by the transportation of essential molecules in the mmpL3 pathway: wherein R1, R2, R3, R4, R5 and R6 are as defined herein.Type: ApplicationFiled: September 5, 2013Publication date: June 25, 2015Applicant: Novartis AGInventors: Jan Jiricek, Ravinder Reddy Kondreddi, Paul William Smith
-
Patent number: 8288412Abstract: Compounds of formula (I) and salts are provided: wherein R5 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; R6 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.Type: GrantFiled: September 27, 2006Date of Patent: October 16, 2012Assignee: Glaxo Group LimitedInventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
-
Patent number: 8288413Abstract: Compounds of formula (I) and salts are provided: wherein R6 is selected from hydrogen, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.Type: GrantFiled: September 27, 2006Date of Patent: October 16, 2012Assignee: Glaxo Group LimitedInventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
-
Patent number: 8283364Abstract: Compounds of formula (I) and salts are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.Type: GrantFiled: September 27, 2006Date of Patent: October 9, 2012Assignee: Glaxo Group LimitedInventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
-
Publication number: 20080306112Abstract: Compounds of formula (I) and salts are provided: wherein R6 is selected from hydrogen, halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano, and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.Type: ApplicationFiled: September 27, 2006Publication date: December 11, 2008Inventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
-
Publication number: 20080293770Abstract: Compounds of formula (I) and salts are provided: wherein R5 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; R6 is selected from halogen, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6 alkoxy, C1-6 alkoxy substituted with one or more fluorine atoms, and cyano; and Q is hydrogen or C1-6alkyl. The compounds are M1 agonists and are useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.Type: ApplicationFiled: September 27, 2006Publication date: November 27, 2008Applicant: Glaxo Group LimitedInventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
-
Publication number: 20080261945Abstract: The present invention relates to compounds of formula (I), a pharmaceutically acceptable salt, solvate or prodrug thereof: wherein R1 is phenyl optionally substituted by 1, 2 or 3 halogen atoms which halogen atoms may be the same or different; R2 is C1-6alkyl, C3-6cycloalkyl or acetyl; X is oxygen or sulphur; a is 1, 2 or 3; b is 0 or 1; c is 0, 1 or 2; R3 is hydrogen or C1-6alkyl; R4 is hydrogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxyC1-6alkyl, C3-6cycloalkyl or C3-6cycloalkylC1-6alkyl; R5 is hydrogen; or R5 and R3, together with the interconnecting atoms, form a 4, 5 or 6 membered ring; R6 is phenyl or thienyl, either of which is optionally substituted by 1, 2 or 3 halogen atoms, which atoms may be the same or different; and z is 0, 1 or 2; wherein when z is 1 or 2, Z is a halogen atom, and wherein when z is 2 the halogen atoms may be the same or different.Type: ApplicationFiled: November 10, 2005Publication date: October 23, 2008Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Paul William Smith, Paul Adrian Wyman
-
Publication number: 20080255195Abstract: Compounds of formula (I) and salts are provided: wherein R4 is fluoro, R5 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one or more fluorine atoms; and R6 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one or more fluorine atoms, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one or more fluorine atoms, and Q is hydrogen or C1-6alkyl. The compounds are expected to be useful for therapy, for example in the treatment of psychotic disorders and cognitive impairment.Type: ApplicationFiled: September 27, 2006Publication date: October 16, 2008Inventors: Brian Budzik, David Gwyn Cooper, Ian Thomson Forbes, Vincenzo Garzya, Jian Jin, Dongchuan Shi, Paul William Smith, Graham Walker
-
Publication number: 20080103173Abstract: The present invention relates to compounds of formula (I), a pharmaceutically acceptable salt or solvate thereof: wherein n, m and p, which may be the same or different, are either 0 or 1. Also disclosed are processes for their preparation, pharmaceutical compositions containing them and their use as medicaments particularly in treating disorders of the central nervous system (CNS).Type: ApplicationFiled: November 10, 2005Publication date: May 1, 2008Applicant: SMITHKLINE BEECHAM CORPORATIONInventors: Roderick Alan Porter, Paul William Smith
-
Patent number: 7179835Abstract: The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.Type: GrantFiled: November 13, 2002Date of Patent: February 20, 2007Assignee: Glaxo Group LimitedInventors: Alan David Borthwick, Matthew Campbell, Chuen Chan, Henry Anderson Kelly, Nigel Paul King, Savvas Kleanthous, Andrew McMurtrie Mason, Stefan Senger, Paul William Smith, Nigel Stephen Watson, Robert John Young